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Abstract
• Undifferentiated connective tissue disease (UCTD) is an
autoimmune disease that presents similarly to other rheumatic
conditions but fails to meet laboratory requirements which indicate a
specific disease such as rheumatoid arthritis, systemic lupus
erythematous, Sjogren's or scleroderma.
• UCTD presentation can include arthralgias, myalgias, fatigue, fever,
Raynaud’s phenomenon and sicca like symptoms with a positive
antinuclear antibody (ANA) test.
• Patients with UCTD symptoms are normally referred to rheumatology
but a shortage exists leaving primary care providers to treat UCTD
patients.
• Using disease modifying antirheumatic drugs (DMARDs) such as
hydroxychloroquine is an option but it is not commonly prescribed by
PCPs.
• The study’s purpose is to determine if PCPs can effectively initiate
and appropriately manage UCTD patients using DMARDs, such as
hydroxychloroquine, to reduce the patient’s symptoms and functional
impairment.
• Using DMARDs, NSAIDs and low dose corticosteroids in UCTD
patients provided by PCPs can improve arthralgias, myalgias, fever,
and functional limitations.
• Majority of rheumatologists and PCPs feel UCTD patients should be
referred to rheumatology for treatment, yet there is some evidence
that PCPs can also initiate and manage the treatment effectively.
• In the absence of rheumatology, PCPs using DMARDs such as
hydroxychloroquine can safely and effectively provide treatment for
these patients

Introduction
• UCTD is also known as incomplete lupus erythematosus,
undifferentiated systemic rheumatic disease, latent lupus, and
potential lupus.
• Rheumatology shortage of 50% by 2025: UCTD patients will face
long wait times and declined referrals. (Basen, 2016).
• DMARDs, such as hydroxychloroquine: proven effective in treating
patients with UCTD, SLE, and RA.
• Primary care providers (PCP) play a key part in early recognition
and referral of patients with UCTD symptoms.
• Scholarly project focus is review of available literature which
demonstrates the use of csDMARDs by PCPs in treating UCTD
patients.
• Projected outcome is that pain and functional impairment can be
decreased via treatment by PCP’s using hydroxychloroquine in the
absence of rheumatology intervention.

Statement of the Problem
• Use of csDMARDs by rheumatologists has the potential to control
rheumatic diseases.
• UCTD patients often lack access to timely treatment by
rheumatology.
• Delaying treatment may result in ongoing symptoms such as but not
limited to arthralgias, myalgias, and functional impairment.
• UCTD patients who do not have access to rheumatologists frequently
look to their primary care providers for treatment
• Question: Is it possible to effectively decrease the inherent
symptoms of UCTD by offering early interventions using csDMARDs
such as hydroxychloroquine through a primary care provider?

Discussion
• Puchner et al. (2016) and Badley et al. (2015) identified the role of
primary care providers to be significant in treating early connective
tissue disease due to the rheumatology shortages.
• Small percentage of the primary care physicians acknowledged
having initiated DMARD therapy, but the majority of general
practitioners pointed out that they would prescribe DMARDs.
(Puchner et al., 2016)
• Possible delays in referrals to rheumatology resulted in long-term
harm, including joint inflammation and destruction
• Primary care providers comfort level and knowledge of DMARD
therapy use can be limiting factors

Berman, J. R. (2017, July). Undifferentiated Connective Tissue Disease: In-Depth Overview. Retrieved from
https://www.hss.edu/conditions_undifferentiated-connective-tissue-disease-overview.asp.

• Current studies have provided significant data supporting the use of
DMARDs in treating UCTD, but there is minimal evidence that
supports the use of DMARDs by primary care providers.

Research Question
In the absence of rheumatology, can primary care providers effectively
initiate and appropriately manage patients with UCTD using
conventional synthetic disease modifying antirheumatic drugs, such as
hydroxychloroquine, to reduce patient’s symptoms and functional
impairment?

Literature Review
Clinical and Serological Presentation of UCTD
• UCTD clinical course includes Raynaud’s phenomenon, sicca
symptoms, arthralgias, arthritis and mucocutaneous manifestations photosensitivity, malar rash, and oral aphthous ulcers as well as a
positive ANA for at least 3 years (Mosca, 2004)
Prevalence of UCTD
• UCTD patients are predominantly middle-aged females with disease
onset between 32-44 years of age. (Conti et al., 2010)
• 20% of newly referred patients to rheumatology may fall within the
undifferentiated profile excluding rheumatoid arthritis. (Mosca et al.
2011)
• Between 50-70% patients remain undifferentiated. (Conti et al., 2010
& Mosca et al., 2011)
Prescriptive Treatment Methods for UCTD
• Use of hydroxychloroquine, NSAIDs, and low dose corticosteroids
was sufficient to maintain UCTD in an inactive status including a
reduction of arthralgias, functional limitations, myalgias and fever.
(Conti et al., 2010).
• It is recommended that early UCTD patients have strict follow up at
least every six months. (Conti et al., 2010).
• One-third of rheumatologists and general practitioners agreed that
when rheumatology availability is limited, then csDMARDs could also
be initiated by a general practitioner. (Puchner et al., 2016).
Role of Primary Care in the Management of UCTD
• On average, 10.3% of the patients made at least one visit to primary
care for inflammatory arthritis. (Badley et al., 2015)
• Primary care providers were less likely to use csDMARDs to treat
connective tissue disease symptoms. (Badley et al., 2015)
• DMARD treatment in primary care was imperative because
unnecessary referrals of patients diagnosed with rheumatic condition
increased the work overload in rheumatology practices. (Puchner et
al., 2016).
• Although csDMARD therapy is not commonly initiated by primary
care physicians, DMARDs are recommended, especially when timely
access to rheumatologists is limited. (James et al., 2007).

Clinical Features of UCTD

Applicability to Clinical
Practice
• Primary care providers have an opportunity to greatly impact the
progression and detrimental effects of UCTD using early
csDMARDs therapy.
• Given the gap and lack of accessibility to rheumatologists by
patients with UCTD, health care sector could collaborate with
primary care providers to offer formal training.
• Rheumatology organizations should consider the possibility of
working with physician assistant programs and schools of nursing to
integrate rheumatology into the curriculum. (Solomon et al., 2014)
• Greater comfort in prescribing DMARDs could be achieved by
altering the design of educational programs for primary care
providers. (Gerneau et al., 2012).
• There continues to be a need for improving awareness and
education regarding diagnosing and treating UCTD patients in
primary care where early treatments with DMARDs make a
significant impact on a patient’s health and quality of life.

% Patients

Fatigue

83

Raynaud’s syndrome

61

Arthralgia

56

Muscle pains

56

Fever

51

Polyarthritis

51

Xerophthalmia

29

Xerostomia

27

Weight loss

24

Thyroiditis

19

Oral aphthosis

17

Lymphadenopathy

17

Urticaria

17

Synovitis

15

Serositis

14

Photosensitivity

12

Erythema nodosum

9

Other

7
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